PACIFIC: Overall Survival with Durvalumab versus Placebo after Chemoradiotherapy in Stage III NSCLC

被引：3
|
作者：
Raben, D. [1 ]
Faivre-Finn, C. [2 ]
Spigel, D. [3 ]
Daniel, D. [3 ,4 ]
Villegas, A. [5 ]
Vincente, D. [6 ]
Hui, R. [7 ,8 ]
Carpeno, J. de Castro [9 ]
Murakami, S. [10 ]
Paz-Ares, L. [11 ,12 ]
Ozguroglu, M. [13 ]
Kurata, T. [14 ]
Chiappori, A. [15 ]
Lee, K. H. [16 ]
de Wit, M. [17 ]
Poole, L. [18 ]
Wadsworth, C. [19 ]
Dennis, P. A. [20 ]
Antonia, S. J. [15 ]
机构：
[1] Univ Colorado, Ctr Canc, Aurora, CO USA
[2] Univ Manchester, Div Canc Sci, Manchester, Lancs, England
[3] Sarah Cannon Res Inst, Nashville, TN USA
[4] Tennessee Oncol, Chattanooga, TN USA
[5] Canc Specialists North Florida, Jacksonville, FL USA
[6] Hosp Univ Virgen Macarena, Seville, Spain
[7] Westmead Hosp, Sydney, NSW, Australia
[8] Univ Sydney, Sydney, NSW, Australia
[9] Hosp Univ La Paz, Madrid, Spain
[10] Kanagawa Canc Ctr, Yokohama, Kanagawa, Japan
[11] Univ Complutense, Hosp Univ Octubre 12, CiberOnc, Madrid, Spain
[12] CNIO, Madrid, Spain
[13] Istanbul Univ Cerrahpasa, Cerrahpasa Med Sch, Istanbul, Turkey
[14] Kansai Med Univ Hosp, Hirakata, Osaka, Japan
[15] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[16] Chungbuk Natl Univ, Chungbuk Natl Univ Hosp, Coll Med, Cheongju, South Korea
[17] Vivantes Klinikum Neukoelln, Berlin, Germany
[18] AstraZeneca, Cambridge, England
[19] AstraZeneca, Alderley Pk, England
[20] AstraZeneca, Gaithersburg, MD USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2018年 / 102卷 / 05期
关键词：
D O I：
10.1016/j.ijrobp.2018.08.057
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA10
引用
收藏
页码：1607 / 1608
页数：2
相关论文
共 50 条
  • [21] PACIFIC-6: A Phase II Study of Durvalumab after sequential Chemoradiotherapy in Patients with unresectable Stage III NSCLC
    Wuerschmidt, F.
    Garassino, M.
    Faivre-Finn, C.
    Mazieres, J.
    Emeribe, U.
    Franks, A.
    Trunova, N.
    Reck, M.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2020, 196 (SUPPL 1) : S88 - S88
  • [22] Safety and efficacy outcomes with durvalumab after sequential chemoradiotherapy (sCRT) in stage III, unresectable NSCLC (PACIFIC-6)
    Garassino, M. C.
    Mazieres, J.
    Reck, M.
    Chouaid, C.
    Bischoff, H.
    Reinmuth, N.
    Cove-Smith, L.
    Mansy, T.
    Cortinovis, D.
    Migliorino, M. R.
    Delmonte, A.
    Sanchez, J. Garcia
    Velarde, L. E. Chara
    Bernabe, R.
    Paz-Ares, L.
    Perez, I. Diaz
    Trunova, N.
    Foroutanpour, K.
    Faivre-Finn, C.
    ANNALS OF ONCOLOGY, 2022, 33 : S81 - S82
  • [23] DURVALUMAB AFTER CHEMORADIOTHERAPY FOR PD-L1 EXPRESSING INOPERABLE STAGE III NSCLC IMPACTS LOCAL-REGIONAL CONTROL AND OVERALL SURVIVAL
    Kaesmann, Lukas
    Taugner, Julian
    Eze, Chukwuka
    Belka, Claus
    Manapov, Farkhad
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A170 - A170
  • [24] PACIFIC-5: Phase III study of durvalumab after either concurrent or sequential chemoradiotherapy (CRT) in patients with stage III NSCLC
    Wu, Y-L.
    Wang, L.
    Sendur, M. A. N.
    Kim, Y-C.
    Zhu, Z.
    Cheng, Y.
    Li, P.
    Qin, Y.
    Macpherson, E.
    Dennis, P. A.
    Lu, S.
    ANNALS OF ONCOLOGY, 2019, 30
  • [25] Impact of Lymphopenia Recovery After Chemoradiotherapy on Durvalumab Consolidation Therapy in Stage III NSCLC
    Kuge, Tomoki
    Shiroyama, Takayuki
    Tamiya, Akihiro
    Tamiya, Motohiro
    Kanazu, Masaki
    Kinehara, Yuhei
    Tanaka, Tsunehiro
    Morimura, Osamu
    Taniguchi, Yoshihiko
    Niki, Toshie
    Tetsumoto, Satoshi
    Hayashi, Kazuhiko
    Nishino, Kazumi
    Nagatomo, Izumi
    Kumanogoh, Atsushi
    JTO CLINICAL AND RESEARCH REPORTS, 2023, 4 (05):
  • [26] Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC)
    Faivre-Finn, Corinne
    Spigel, David R.
    Senan, Suresh
    Langer, Corey
    Perez, Bradford A.
    Ozguroglu, Mustafa
    Daniel, Davey
    Villegas, Augusto
    Vicente, David
    Hui, Rina
    Murakami, Shuji
    Paz-Ares, Luis
    Broadhurst, Helen
    Wadsworth, Catherine
    Dennis, Phillip A.
    Antonia, Scott J.
    LUNG CANCER, 2021, 151 : 30 - 38
  • [27] PACIFIC-R: Real-world characteristics of unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy
    McDonald, F.
    Mornex, F.
    Garassino, M. C.
    Filippi, A. R.
    Christoph, D.
    Haakensen, V. D.
    Agbarya, A.
    Van den Heuvel, M.
    Vercauter, P.
    Chouaid, C.
    Pichon, E.
    Siva, S.
    Steinbusch, L.
    Peretz, I.
    Solomon, B.
    Decoster, L.
    Sawyer, W.
    Allen, A.
    Licour, M.
    Girard, N.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S738 - S739
  • [28] Analysis of the Influence of volumetric Radiation Parameters on the Overall Survival of Patients with inoperable Stage III NSCLC after Chemoradiotherapy
    Taugner, J.
    Kaesmann, L.
    Eze, C.
    Dantes, M.
    Roengvoraphoj, O.
    Belka, C.
    Manapov, F.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2020, 196 (SUPPL 1) : S149 - S149
  • [29] The Incidence of Brain Metastasis and Radiation Pneumonitis With Durvalumab After Chemoradiotherapy in Unresectable Stage III NSCLC
    Kim, Y.
    Choi, Y-K
    Kwak, Y-K
    Lee, Y-H
    Kim, S-H
    Sung, S-Y
    Son, S-H
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S281 - S281
  • [30] Factors associated with receipt and overall survival of concurrent Chemoradiotherapy versus single modality therapy in Unresectable stage III NSCLC
    DerSarkissian, Maral
    Ryan, Kellie
    Duh, Mei Sheng
    Satija, Ambika
    Bobbili, Priyanka J.
    Gomez, Jorge E.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 134 - 134
12345